NCT02944162 - CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2018

Conditions

Acute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia With MaturationAcute Myeloid Leukemia Without MaturationANLL

Interventions

BIOLOGICAL

anti-CD33 CAR-NK cells

The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.

Trial Locations (1)

215123

RECRUITING

PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou